Issue Brief CAP’s drug pricing framework would empower Medicare and private payers to negotiate effectively for drug prices, backed by binding arbitration.
Issue Brief Instead of building a system that works for all, House Republicans’ plan to replace the Affordable Care Act would quarantine sick Americans in separate markets, resulting in higher costs and less coverage.
The Center for American Progress supports a proposal from the CMS that would benefit patients by testing different ways to pay for expensive drugs.
Issue Brief Cutting corners by pushing the FDA to approve more drugs on the basis of more limited data will put patients at risk.
Issue Brief Experiences from past mergers show that divestitures most likely will not be a successful remedy in the proposed Aetna-Humana merger.
Report Creating a new Medicaid benefit for evidence-based home visiting services would simplify funding and allow states and communities to scale services, improve outcomes for families, and produce significant savings for states and the federal government.
Neera Tanden and Maura Calsyn write about how to foster drug research while discouraging profiteering.
The current draft of the TPP will raise drug prices and hinder access to critical medications.
Report Medicare’s Pioneer ACO Model has shown modest yet improving results so far. The Centers for Medicare & Medicaid Services should make improvements to the Pioneer ACO Model while also expanding bundled payment reforms.
Issue Brief Targeted reforms will help more Americans afford the long-term care they are likely to need in the coming decades.
Issue Brief Hidden prices drive up costs throughout the health care system. There are a variety of ways to increase transparency, which is key to lowering health care costs.
Maura Calsyn, Director of Health Policy, testifies before the U.S. House Subcommittee on Health, Employment, Labor, and Pensions.